- Home
- PMCB vs MTVA Comparison
PMCB vs MTVA Comparison
Compare PMCB & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- MTVA
- Stock Information
- Founded
- PMCB 1996
- MTVA 2014
- Country
- PMCB United States
- MTVA United States
- Employees
- PMCB N/A
- MTVA N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- MTVA
- Sector
- PMCB Health Care
- MTVA
- Exchange
- PMCB Nasdaq
- MTVA NYSE
- Market Cap
- PMCB 11.4M
- MTVA 12.5M
- IPO Year
- PMCB N/A
- MTVA N/A
- Fundamental
- Price
- PMCB $1.78
- MTVA $1.55
- Analyst Decision
- PMCB
- MTVA Strong Buy
- Analyst Count
- PMCB 0
- MTVA 1
- Target Price
- PMCB N/A
- MTVA $12.00
- AVG Volume (30 Days)
- PMCB 27.8K
- MTVA 25.6K
- Earning Date
- PMCB 03-17-2025
- MTVA 03-27-2025
- Dividend Yield
- PMCB N/A
- MTVA N/A
- EPS Growth
- PMCB N/A
- MTVA N/A
- EPS
- PMCB 0.74
- MTVA N/A
- Revenue
- PMCB N/A
- MTVA N/A
- Revenue This Year
- PMCB N/A
- MTVA N/A
- Revenue Next Year
- PMCB N/A
- MTVA N/A
- P/E Ratio
- PMCB $2.40
- MTVA N/A
- Revenue Growth
- PMCB N/A
- MTVA N/A
- 52 Week Low
- PMCB $1.39
- MTVA $1.29
- 52 Week High
- PMCB $2.58
- MTVA $5.53
- Technical
- Relative Strength Index (RSI)
- PMCB 56.75
- MTVA N/A
- Support Level
- PMCB $1.57
- MTVA N/A
- Resistance Level
- PMCB $1.80
- MTVA N/A
- Average True Range (ATR)
- PMCB 0.13
- MTVA 0.00
- MACD
- PMCB 0.01
- MTVA 0.00
- Stochastic Oscillator
- PMCB 64.10
- MTVA 0.00
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.